Alkermes vs Rhythm Pharmaceuticals
Alkermes (ALKS), health care, and Rhythm Pharmaceuticals (RYTM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Rhythm Pharmaceuticals is worth $8.1B on the stock market and Alkermes $7.6B: Rhythm Pharmaceuticals is valued at 6% more. Alkermes's operating margin in its latest fiscal year was 17.2% and Rhythm Pharmaceuticals's -101%. Over the past year Alkermes's share price has moved +59.0% and Rhythm Pharmaceuticals's +6.93%.
Key facts
- Alkermes market value
- $7.6B
- Rhythm Pharmaceuticals market value
- $8.1B
- Alkermes revenue
- $1.5BFY to 2025-12-31
- Rhythm Pharmaceuticals revenue
- $189.8MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Alkermes | Rhythm Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.6Blower | $8.1Bhigher |
| Revenue | $1.5Bhigher | $189.8Mlower |
| Earnings | $241.7Mhigher | -$196.5Mlower |
| Employees | 2,050higher | 414lower |
| Total assets | $2.5Bhigher | $480.2Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 5.2lower | 42.7higher |
| P/B | — | 92.0 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 17.2%higher | -101%lower |
| Balance sheet | ||
| Net assets | $1.8Bhigher | $139.1Mlower |
| Total liabilities | $667.7Mhigher | $210.2Mlower |
| Total debt | — | $108.2M |
| Cash on hand | $388.6Mhigher | $54.3Mlower |
| Price change | ||
| Today | -2.41%lower | +8.62%higher |
| 1 year | +59.0%higher | +6.93%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Alkermes / Rhythm Pharmaceuticals). Who owns ALKS · Who owns RYTM
More on Alkermes
Further comparisons
Alkermes against its closest peers
Rhythm Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Alkermes or Rhythm Pharmaceuticals?
By market value, Rhythm Pharmaceuticals is the larger: $8.1B against $7.6B for Alkermes. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $189.8M for Rhythm Pharmaceuticals.
Which has the higher operating margin?
Alkermes: 17.2%, against -101% for Rhythm Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Alkermes and Rhythm Pharmaceuticals?
In their latest 13F filings, Julian and Felix Baker holds both.
Cite this page
Funkfolio, “Alkermes vs Rhythm Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-rytm
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.